Amgen

Summary : Five Prime’s lead asset, Bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled…

Summary : While England’s drug-price watchdog continues to assess the value of Amgen’s lung cancer drug Lumykras, the company and the National…

Summary : Amgen has posted a 3% rise in total 2021 fourth-quarter revenues to $6.8 billion and a 2% increase in total revenue for the year…

Summary : Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel…

Synopsis : As a British citizen living in England but writing on American drug names, I’m in a perfect position to know…

Synopsis : Amgen  and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against…

Synopsis- Under the extended contract, the dedicated R&D center, ‘Syngene Amgen Research and Development Center’ (SARC), will continue to conduct drug discovery…

Synopsis- Otezla trumped placebo in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis, top-line results from Amgen’s…

Summary – A U.S. District Court has ruled in favor of Amgen in a patent litigation case involving the drug Enbrel, preventing…